Skip to main content

Advertisement

Log in

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

  • Melanoma (K Margolin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Mucosal melanoma represents a rare subtype of melanoma with distinct biological, clinical, and management considerations. Knowledge regarding optimal treatment strategies for mucosal melanoma is limited and based primarily upon small case series and single-institution, retrospective analyses. Surgery remains the standard of care for loco-regional management, but the common presence of multifocal disease and the high rate of distant recurrence should be considered before pursuing aggressive surgical interventions associated with inherent significant morbidity. The role of sentinel lymph node biopsy and lymph node dissection remains unclear. Radiotherapy has not been shown to improve overall survival but may reduce the rate of local recurrence. Significant advances in the treatment of metastatic disease have been made with novel immunotherapeutic agents, the discovery of KIT and BRAF mutations and the development of targeted agents that inhibit these oncogenic pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •  Of importance •• Of major importance

  1. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin. 2012;62:10–29.

    Article  Google Scholar 

  3. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.

    Article  PubMed  CAS  Google Scholar 

  4. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56:828–34.

    Article  PubMed  Google Scholar 

  5. Garland CF, Garland FC, Gorham ED. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. Ann Epidemiol. 2003;13:395–404.

    Article  PubMed  Google Scholar 

  6. Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer. 1974;34:358–70.

    Article  PubMed  CAS  Google Scholar 

  7. Axell T, Hedin CA. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dental Res. 1982;90:434–42.

    CAS  Google Scholar 

  8. Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol. 2003;88:45–50.

    Article  PubMed  Google Scholar 

  9. Verschraegen CF, Benjapibal M, Supakarapongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer. 2001;11:359–64.

    Article  PubMed  CAS  Google Scholar 

  10. Watanabe J, Yamamoto S, Souma T, et al. Primary malignant melanoma of the male urethra. Int J Urol. 2000;7:3513.

    Article  Google Scholar 

  11. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247–57.

    Article  PubMed  Google Scholar 

  12. Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck. 2008;30:1325–31.

    Article  PubMed  Google Scholar 

  13. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer. 2004;100:1657–64.

    Article  PubMed  Google Scholar 

  14. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003;27:594–611.

    Article  PubMed  Google Scholar 

  15. Pfister DG, Ang KK, Brizel DM, et al. Mucosal melanoma of the head and neck. JNCCN. 2012;10:320–38.

    PubMed  Google Scholar 

  16. Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol. 2006;132:73–8.

    Article  Google Scholar 

  17. Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol. 2009;135:1219–24.

    Article  Google Scholar 

  18. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck. 1991;13:22–7.

    Article  PubMed  CAS  Google Scholar 

  19. Starek I, Koranda P, Benes P. Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res. 2006;16:423–7.

    Article  PubMed  Google Scholar 

  20. Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J. 2007;13:217–22.

    Article  PubMed  CAS  Google Scholar 

  21. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.

    Article  PubMed  CAS  Google Scholar 

  22. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80:1373–86.

    Article  PubMed  CAS  Google Scholar 

  23. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–9.

    Article  PubMed  Google Scholar 

  24. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008;30:1543–51.

    Article  PubMed  Google Scholar 

  25. Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol. 2010;33:281–5.

    PubMed  Google Scholar 

  26. Cote TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res. 2009;19:58–60.

    Article  PubMed  Google Scholar 

  27. Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing 3 decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol. 2010;17:40–4.

    Article  PubMed  Google Scholar 

  28. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum. 1995;38:146–51.

    Article  PubMed  CAS  Google Scholar 

  29. Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006;244:1012–7.

    Article  PubMed  Google Scholar 

  30. Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. Br J Surg. 2004;91:1183–7.

    Article  PubMed  CAS  Google Scholar 

  31. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555–8.

    Article  PubMed  Google Scholar 

  32. Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer. 2011;117:4747–55.

    Google Scholar 

  33. Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlof B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer. 1999;86:1273–84.

    Article  PubMed  CAS  Google Scholar 

  34. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol. 1994;171:1225–30.

    PubMed  CAS  Google Scholar 

  35. Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol. 2007;110(2 Pt 1):296–301.

    Article  PubMed  Google Scholar 

  36. Piura B, Rabinovich A, Yanai-Inbar I. Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol. 2002;23:195–8.

    PubMed  CAS  Google Scholar 

  37. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970;120:425–31.

    Article  PubMed  CAS  Google Scholar 

  38. Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010;116:1358–65.

    Article  PubMed  Google Scholar 

  39. Suwandinata FS, Bohle RM, Omwandho CA, et al. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol. 2007;28:220–4.

    PubMed  CAS  Google Scholar 

  40. de Hullu JA, Hollema H, Hoekstra HJ, et al. Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer. 2002;94:48691.

    Google Scholar 

  41. Dhar KK, Das N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of 2 cases and review of the literature. Int J Gynecol Cancer. 2007;17:720–3.

    Article  PubMed  CAS  Google Scholar 

  42. van Geel AN, den Bakker MA, Kirkels W, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology. 2007;70:143–7.

    Article  PubMed  Google Scholar 

  43. Heath DI, Womack C. Primary malignant melanoma of the gall bladder. J Clin Pathol. 1988;41:1073–7.

    Article  PubMed  CAS  Google Scholar 

  44. Habeck JO. Primary malignant melanoma of the gallbladder. Case report and literature review. Zentralbl Pathol. 1993;139:367–71.

    PubMed  CAS  Google Scholar 

  45. Lam KY, Law S, Wong J. Malignant melanoma of the oesophagus: clinicopathological features, lack of p53 expression and steroid receptors and a review of the literature. Eur J Surg Oncol. 1999;25:168–72.

    Article  PubMed  CAS  Google Scholar 

  46. Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet. 2009;10:516–21.

    Article  Google Scholar 

  47. Blecker D, Abraham S, Furth EE, et al. Melanoma in the gastrointestinal tract. Am J Gastroenterol. 1999;94:3427–33.

    Article  PubMed  CAS  Google Scholar 

  48. Yi JH, Yi SY, Lee HR, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21:223–7.

    Article  PubMed  CAS  Google Scholar 

  49. Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck. 2008;30:1592–8.

    Article  PubMed  Google Scholar 

  50. Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004;100:1478–83.

    Article  PubMed  CAS  Google Scholar 

  51. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res. 2004;14:517–20.

    Article  PubMed  CAS  Google Scholar 

  52. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol. 2007;25:5426–34.

    Article  PubMed  CAS  Google Scholar 

  53. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748–54.

    Article  PubMed  CAS  Google Scholar 

  54. •• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. First phase III study to show an improvement in overall survival for patients with metastatic melanoma. Results of this study contributed to the US FDA approval of ipilimumab..

    Article  PubMed  CAS  Google Scholar 

  55. • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. Second phase III study to demonstrate an improvement in overall survival for patients who received ipilimumab compared to those who did not..

    Article  PubMed  CAS  Google Scholar 

  56. •• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. First demonstration of the overall survival benefit of vemurafenib, the targeted inhibitor of oncogenic BRAF..

    Article  PubMed  CAS  Google Scholar 

  57. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.

    Article  PubMed  CAS  Google Scholar 

  58. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.

    Article  PubMed  CAS  Google Scholar 

  59. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878–90.

    Article  PubMed  CAS  Google Scholar 

  60. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.

    Article  PubMed  CAS  Google Scholar 

  61. Rivera RS, Nagatsuka H, Gunduz M, et al. C-KIT protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008;452:27–32.

    Article  PubMed  CAS  Google Scholar 

  62. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–51.

    Article  PubMed  CAS  Google Scholar 

  63. •• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34. Phase II study showing the efficacy of imatinib for patients with KIT genetic aberrations, including patients with mucosal melanoma who achieved durable partial and complete responses..

    Article  PubMed  CAS  Google Scholar 

  64. •• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J Clin Oncol. 2011;29:2904–9. Phase II study showing the efficacy of imatinib for patients with KIT genetic aberrations..

    Article  PubMed  CAS  Google Scholar 

  65. Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18:1457–63.

    Article  PubMed  CAS  Google Scholar 

  66. Si L, Xu X, Kong Y, et al. Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol. 2012;30:e37–40.

    Article  PubMed  CAS  Google Scholar 

  67. Tsao H, Zhang X, Fowlkes K, et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60:1800–4.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

M. A. Postow: none; O. Hamid: none; R. D. Carvajal: consultant to Novartis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard D. Carvajal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postow, M.A., Hamid, O. & Carvajal, R.D. Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. Curr Oncol Rep 14, 441–448 (2012). https://doi.org/10.1007/s11912-012-0244-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0244-x

Keywords

Navigation